Abstract
Success of anti-infective therapy is a major challenge in some patients given anatomo-physiological changes and genetic variations. In this case anecdote, we report the management strategy of a patient suffering from chronic pulmonary aspergillosis in a context of anorexia nervosa and genetic polymorphism.
Keywords:
cytochrome P450 enzymes; drug metabolism; genetic polymorphism; pharmacogenomics; therapeutic drug monitoring.
© 2018 The British Pharmacological Society.
MeSH terms
-
Administration, Oral
-
Adult
-
Anorexia Nervosa / complications
-
Anorexia Nervosa / physiopathology*
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / pharmacokinetics*
-
Azoles / administration & dosage
-
Azoles / pharmacokinetics*
-
Cytochrome P-450 CYP2C19 / genetics*
-
Cytochrome P-450 CYP2C19 / metabolism
-
Female
-
Humans
-
Intestinal Absorption / physiology
-
Pharmacogenomic Testing
-
Polymorphism, Single Nucleotide
-
Pulmonary Aspergillosis / complications
-
Pulmonary Aspergillosis / drug therapy*
-
Treatment Outcome
Substances
-
Antifungal Agents
-
Azoles
-
CYP2C19 protein, human
-
Cytochrome P-450 CYP2C19